Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Kidney Fibrosis Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Kidney Fibrosis Overview | 11 | 1 |
| Pipeline Products for Kidney Fibrosis Comparative Analysis | 12 | 1 |
| Kidney Fibrosis Therapeutics under Development by Companies | 13 | 2 |
| Kidney Fibrosis Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Kidney Fibrosis Pipeline Products Glance | 16 | 2 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Kidney Fibrosis Products under Development by Companies | 18 | 2 |
| Kidney Fibrosis Products under Investigation by Universities/Institutes | 20 | 1 |
| Kidney Fibrosis Companies Involved in Therapeutics Development | 21 | 20 |
| AbbVie Inc | 21 | 1 |
| Angion Biomedica Corp. | 22 | 1 |
| Bio-inRen | 23 | 1 |
| BiOrion Technologies B.V. | 24 | 1 |
| Cellmid Limited | 25 | 1 |
| Epigen Biosciences, Inc. | 26 | 1 |
| Evotec AG | 27 | 1 |
| Galectin Therapeutics, Inc. | 28 | 1 |
| GenKyoTex S.A. | 29 | 1 |
| Intercept Pharmaceuticals, Inc. | 30 | 1 |
| Isarna Therapeutics GmbH | 31 | 1 |
| Lpath, Inc. | 32 | 1 |
| MorphoSys AG | 33 | 1 |
| Pharmaxis Limited | 34 | 1 |
| ProMetic Life Sciences Inc. | 35 | 1 |
| Raptor Pharmaceutical Corp. | 36 | 1 |
| Regulus Therapeutics Inc. | 37 | 1 |
| Symic Biomedical, Inc. | 38 | 1 |
| Tobira Therapeutics, Inc. | 39 | 1 |
| Vascular Biogenics Ltd. | 40 | 1 |
| Kidney Fibrosis Therapeutics Assessment | 41 | 11 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Target | 42 | 3 |
| Assessment by Mechanism of Action | 45 | 3 |
| Assessment by Route of Administration | 48 | 2 |
| Assessment by Molecule Type | 50 | 2 |
| Drug Profiles | 52 | 70 |
| ANG-3070 Drug Profile | 52 | 1 |
| ANG-3586 Drug Profile | 53 | 1 |
| ANG-4021 Drug Profile | 54 | 1 |
| BOT-191 Drug Profile | 55 | 1 |
| BRN-1889 Drug Profile | 56 | 1 |
| CAB-102 Drug Profile | 57 | 2 |
| cenicriviroc mesylate Drug Profile | 59 | 7 |
| CT-140 Drug Profile | 66 | 1 |
| cysteamine DR Drug Profile | 67 | 8 |
| Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis Drug Profile | 75 | 1 |
| Drugs for Tissue Fibrosis Drug Profile | 76 | 1 |
| Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis Drug Profile | 77 | 1 |
| GKT-136901 Drug Profile | 78 | 1 |
| GRMD-02 Drug Profile | 79 | 11 |
| ICG-001 Drug Profile | 90 | 1 |
| INT-767 Drug Profile | 91 | 1 |
| ISTH-0047 Drug Profile | 92 | 2 |
| LJ-1888 Drug Profile | 94 | 1 |
| Lpathomab Drug Profile | 95 | 3 |
| melittin Drug Profile | 98 | 1 |
| MOR-107 Drug Profile | 99 | 1 |
| P-007 Drug Profile | 100 | 1 |
| PBI-4050 Drug Profile | 101 | 5 |
| PBI-4419 Drug Profile | 106 | 1 |
| PXS-4820 Drug Profile | 107 | 1 |
| PXS-5033A Drug Profile | 108 | 1 |
| Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis Drug Profile | 109 | 2 |
| RG-012 Drug Profile | 111 | 3 |
| SB-300 Drug Profile | 114 | 1 |
| Small Molecule to Antagonize AlphaVBetaI for Fibrosis Drug Profile | 115 | 1 |
| Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis Drug Profile | 116 | 1 |
| Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis Drug Profile | 117 | 1 |
| Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology Drug Profile | 118 | 1 |
| SOL-1 Drug Profile | 119 | 1 |
| Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis Drug Profile | 120 | 1 |
| VB-703 Drug Profile | 121 | 1 |
| Kidney Fibrosis Dormant Projects | 122 | 1 |
| Kidney Fibrosis Product Development Milestones | 123 | 7 |
| Featured News &Press Releases | 123 | 1 |
| Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis | 123 | 1 |
| Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics | 123 | 1 |
| Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting | 124 | 1 |
| Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 | 125 | 2 |
| Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases | 127 | 1 |
| Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting | 127 | 1 |
| Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter | 128 | 1 |
| Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis | 128 | 1 |
| Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting | 129 | 1 |
| Appendix | 130 | 2 |
| Methodology | 130 | 1 |
| Coverage | 130 | 1 |
| Secondary Research | 130 | 1 |
| Primary Research | 130 | 1 |
| Expert Panel Validation | 130 | 1 |
| Contact Us | 130 | 1 |
| Disclaimer | 131 | 1 |
